Sellas Life Sciences Group is a biotechnology business based in the US. Sellas Life Sciences Group shares (SLS) are listed on the NASDAQ and all prices are listed in US Dollars. Sellas Life Sciences Group employs 11 staff and has a trailing 12-month revenue of around $1 million.
How to buy Sellas Life Sciences Group stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – SLS. It's that simple.
SoFi Invest
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
eToro
- Trade stocks and ETFs for $0 and no annual fee
- Minimum deposit of $10 required
- FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100
Robinhood
- Get free stock upon signup
- Earn 4% interest on uninvested cash with Robinhood Gold
- Get 1% match on contributions to a Robinhood IRA
Sellas Life Sciences Group stock price (NASDAQ: SLS)
Use our graph to track the performance of SLS stocks over time.Sellas Life Sciences Group shares at a glance
Latest market close | $3.30 |
---|---|
52-week range | $1.77 - $7.40 |
50-day moving average | $2.65 |
200-day moving average | $2.81 |
Wall St. target price | $8.00 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-2.23 |
Buy Sellas Life Sciences Group stocks from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Sellas Life Sciences Group stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Sellas Life Sciences Group price performance over time
Historical closes compared with the close of $3.3 from 2023-02-01
1 week (2023-01-26) | -2.94% |
---|---|
1 month (2022-12-30) | 39.83% |
3 months (2022-11-02) | -17.29% |
6 months (2022-08-02) | 24.06% |
1 year (2022-02-01) | -40.54% |
---|---|
2 years (2021-02-02) | -59.66% |
3 years (2020-01-31) | 18.28% |
5 years (2018-02-02) | 5.93 |
Sellas Life Sciences Group financials
Revenue TTM | $1 million |
---|---|
Gross profit TTM | $7.4 million |
Return on assets TTM | -55.55% |
Return on equity TTM | -197.83% |
Profit margin | 0% |
Book value | $0.61 |
Market capitalisation | $67.9 million |
TTM: trailing 12 months
Sellas Life Sciences Group share dividends
We're not expecting Sellas Life Sciences Group to pay a dividend over the next 12 months.
Have Sellas Life Sciences Group's shares ever split?
Sellas Life Sciences Group's shares were split on a 1:50 basis on 7 November 2019. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sellas Life Sciences Group shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for Sellas Life Sciences Group shares which in turn could have impacted Sellas Life Sciences Group's share price.
Sellas Life Sciences Group share price volatility
Over the last 12 months, Sellas Life Sciences Group's shares have ranged in value from as little as $1.77 up to $7.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sellas Life Sciences Group's is 2.1636. This would suggest that Sellas Life Sciences Group's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Sellas Life Sciences Group overview
SELLAS Life Sciences Group, Inc. , a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co. , Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors.
Sellas Life Sciences Group in the news
SELLAS Life Sciences to Host Key Opinion Leader Webinar on Galinpepimut-S Acute Myeloid Leukemia Program
SELLAS Life Sciences to Host Key Opinion Leader Webinar on Galinpepimut-S Acute Myeloid Leukemia Program
SELLAS Life Sciences Strengthens Leadership Team with Appointment of Vice President Head of Regulatory Affairs
Frequently asked questions
What percentage of Sellas Life Sciences Group is owned by insiders or institutions?Currently 0.088% of Sellas Life Sciences Group shares are held by insiders and 10.781% by institutions. How many people work for Sellas Life Sciences Group?
Latest data suggests 11 work at Sellas Life Sciences Group. When does the fiscal year end for Sellas Life Sciences Group?
Sellas Life Sciences Group's fiscal year ends in December. Where is Sellas Life Sciences Group based?
Sellas Life Sciences Group's address is: Times Square Tower, New York, NY, United States, 10036 What is Sellas Life Sciences Group's ISIN number?
Sellas Life Sciences Group's international securities identification number is: US81642T2096 What is Sellas Life Sciences Group's CUSIP number?
Sellas Life Sciences Group's Committee on Uniform Securities Identification Procedures number is: 74978T109
More guides on Finder
-
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
-
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
-
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
-
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
-
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
-
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
-
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
-
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
-
How to research stocks
Learn about stock analysis and how to use it to find the right company to buy.
Ask an Expert